Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Neuroendocrine Tumors × Tamoxifen × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Breast Neoplasms 142 Carcinoma, Intraductal, Noninfiltrating 14 Breast Carcinoma In Situ 10 Neoplasm Metastasis 9 Breast Neoplasms, Male 7 Ovarian Neoplasms 6 Neoplasms 4 Inflammatory Breast Neoplasms 3 Glioblastoma 3 Breast Cancer Female 3 Urinary Bladder Neoplasms 2 Recurrence 2 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Obesity 2 Hot Flashes 2 Fibroadenoma 2 Endometrial Neoplasms 2 ER+ Breast Cancer 2 Brain Neoplasms 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Sleep Wake Disorders 1 Sexuality 1 Risk Reduction Behavior 1 Primary Breast Cancer 1 Premenopausal Breast Cancer 1 Precancerous Conditions 1 Patient Acceptance of Health Care 1 Oligodendroglioma 1

Interventions

lutetium Lu 177 dotatate 28 Everolimus 17 Magnetic Resonance Spectroscopy 10 gallium Ga 68 dotatate 9 Temozolomide 9 Capecitabine 9 lanreotide 8 Nivolumab 8 Positron Emission Tomography Computed Tomography 7 177Lu-octreotide, DOTA(0)-Tyr(3)- 7 cabozantinib 6 Somatostatin 6 90Y-octreotide, DOTA-Tyr(3)- 6 3-Iodobenzylguanidine 6 pembrolizumab 5 Octreotide 5 Lutetium-177 5 Ga(III)-DOTATOC 5 Fluorodeoxyglucose F18 5 telotristat ethyl 4 avelumab 4 Carboplatin 4 Bevacizumab 4 Al18F-NOTA-octreotide 4 pasireotide 3 lenvatinib 3 fluorodopa F 18 3 copper dotatate CU-64 3 Surveys and Questionnaires 3 Single Photon Emission Computed Tomography Computed Tomography 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03870399 2024-05-06

HORMONET

AC Camargo Cancer Center

Phase 2 Completed

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡